Q-omics provides the consensus-scored DAG1 profile across patient tissues and cancer cell-line models. DAG1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, DAG1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, DAG1 protein abundance shows 22,223 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight MESO, KIRC, and HNSC as cancer lineages where DAG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DAG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DAG1 survival associations across molecular data types. DAG1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DAG1 RNA expression–survival associations across cancer types. High DAG1 expression shows unfavorable associations in MESO, LGG and ACC, but favorable associations in HNSC, UCS and BRCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for DAG1 RNA expression.
This table summarizes DAG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DAG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DAG1 shows lower tumor expression in KIRC and higher tumor expression in LIHC, STAD, BLCA, HNSC and BRCA. The KIRC box plot shows higher DAG1 RNA expression in normal versus tumor tissue (log2 FC = −0.989, t-test p < 0.001).
This table shows molecular features associated with DAG1 in patient tissues and cancer cell lines. In patient samples, DAG1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, DAG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
